EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Doxorubicin-conjugated siRNA lipid nanoparticles for combination cancer therapy

Kamila Butowska, Xuexiang Han, Ningqiang Gong, Rakan El-Mayta, Rebecca M Haley, Lulu Xue, Wenqun Zhong, Wei Guo, Karin Wang, Michael J Mitchell

Acta Pharmaceutica Sinica B · 2023-04 · 13 (4) · 1429-1437

DOI: 10.1016/j.apsb.2022.07.011 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Pharmaceutica Sinica B, 2023-04. Verfasst von Kamila Butowska und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioengineering, University of Pennsylvania, Philadelphia, PA 19104, USA. Die Arbeit wurde bisher 82-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Narodowa Agencja Wymiany Akademickiej, American Cancer Society, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

Bcl-2ChemotherapyDoxorubicinLipid nanoparticlesLymphomasiRNA delivery

Autor:innen und Institutionen

  • Department of Bioengineering, University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Intercollegiate Faculty of Biotechnology, University of Gdańsk & Medical University of Gdańsk, Gdańsk 80-307, Poland.
  • Department of Biology, University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Department of Bioengineering, Temple University, Philadelphia, PA 19122, USA.
  • Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

Förderung

  • Narodowa Agencja Wymiany Akademickiej
  • American Cancer Society
  • National Cancer Institute
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • Burroughs Wellcome Fund
  • Canadian Aeronautics and Space Institute
  • National Institutes of Health
  • National Science Foundation

Zitieren

APA

Butowska, K., Han, X., Gong, N., El-Mayta, R., Haley, R. M., Xue, L., Zhong, W., Guo, W., Wang, K., & Mitchell, M. J. (2023). Doxorubicin-conjugated siRNA lipid nanoparticles for combination cancer therapy. Acta Pharmaceutica Sinica B, 13(4), 1429-1437. https://doi.org/10.1016/j.apsb.2022.07.011

Vancouver

Butowska K, Han X, Gong N, El-Mayta R, Haley RM, Xue L, et al. Doxorubicin-conjugated siRNA lipid nanoparticles for combination cancer therapy. Acta Pharmaceutica Sinica B. 2023;13(4):1429-1437. doi:10.1016/j.apsb.2022.07.011

BibTeX
@article{Butowska2023,
  author = {Butowska, Kamila and Han, Xuexiang and Gong, Ningqiang and El-Mayta, Rakan and Haley, Rebecca M and Xue, Lulu and Zhong, Wenqun and Guo, Wei and Wang, Karin and Mitchell, Michael J},
  title = {Doxorubicin-conjugated siRNA lipid nanoparticles for combination cancer therapy},
  journal = {Acta Pharmaceutica Sinica B},
  year = {2023},
  volume = {13},
  number = {4},
  pages = {1429--1437},
  doi = {10.1016/j.apsb.2022.07.011}
}
Kostenlos starten →